Criteria for the diagnosis of corticobasal degeneration
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Current criteria for the clinical diagnosis of pathologically confirmed corticobasal degeneration (CBD) no longer reflect the expanding understanding of this disease and its clinicopathologic correlations. An international consortium of behavioral neurology, neuropsychology, and movement disorders specialists developed new criteria based on consensus and a systematic literature review. Clinical diagnoses (early or late) were identified for 267 nonoverlapping pathologically confirmed CBD cases from published reports and brain banks. Combined with consensus, 4 CBD phenotypes emerged: corticobasal syndrome (CBS), frontal behavioral-spatial syndrome (FBS), nonfluent/agrammatic variant of primary progressive aphasia (naPPA), and progressive supranuclear palsy syndrome (PSPS). Clinical features of CBD cases were extracted from descriptions of 209 brain bank and published patients, providing a comprehensive description of CBD and correcting common misconceptions. Clinical CBD phenotypes and features were combined to create 2 sets of criteria: more specific clinical research criteria for probable CBD and broader criteria for possible CBD that are more inclusive but have a higher chance to detect other tau-based pathologies. Probable CBD criteria require insidious onset and gradual progression for at least 1 year, age at onset ≥50 years, no similar family history or known tau mutations, and a clinical phenotype of probable CBS or either FBS or naPPA with at least 1 CBS feature. The possible CBD category uses similar criteria but has no restrictions on age or family history, allows tau mutations, permits less rigorous phenotype fulfillment, and includes a PSPS phenotype. Future validation and refinement of the proposed criteria are needed. AD= : Alzheimer disease; AOS= : apraxia of speech; CBD= : corticobasal degeneration; CBS= : corticobasal syndrome; CJD= : Creutzfeldt-Jakob disease; cr-CBD= : clinical research criteria for probable corticobasal degeneration; DLB= : dementia with Lewy bodies; FTD= : frontotemporal dementia; FTLD-TDP= : frontotemporal lobar degeneration with TDP-43 immunoreactive inclusions; GRN= : granulin; p-CBD= : possible corticobasal degeneration criteria; PD= : Parkinson disease; PNFA= : progressive nonfluent aphasia; PPA= : primary progressive aphasia; PSP= : progressive supranuclear palsy; PSPS= : progressive supranuclear palsy syndrome
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical diagnosis of the FTD variants was based on current criteria (Armstrong et al., 2013; Gorno-Tempini et al., 2011; Rascovsky & Grossman, 2013; Rascovsky et al., 2011).”
From Multiclass characterization of frontotemporal dementia variants via multimodal brain network computational inference (2023) · cites this paper as Armstrong et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other phenotypes, including the behavioural variant or dysexecutive variant,95,96 the corticobasal variant,97,98 and the other variants of primary progressive aphasia94,99 (appendix p 2), are less commonly related to Alzheimer’s disease pathology (uncommon Alzheimer’s disease phenotypes).”
From Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group (2021) · cites this paper as [97]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Classification of primary progressive aphasia and its variants
Gorno-Tempini, M. L., Hillis, A. E., Weintraub, S., Kertesz, A., Mendez, M., Cappa, S. F., Ogar, J. M., Rohrer, J. D., Black, S., Boeve, B. F., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31821103e6 · Cited by 5,141 · cited 1×
“Reports most commonly categorized the aphasia as primary progressive aphasia (PPA), progressive aphasia, or progressive nonfluent aphasia (PNFA), though these terms overlap and reflect older terminology that has recently been revised.(35) Aphasic patients with CBD may progress to mutism.”
BackgroundSelf-citationThe accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service
Hughes, A. J., Daniel, S. E., Ben‐Shlomo, Y., & Lees, A. J. (2002) · Brain · doi:10.1093/brain/awf080 · Cited by 1,251
Office of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration
Dickson, D. W., Bergeron, C., Chin, S. S., Duyckaerts, C., Horoupian, D., Ikeda, K., Jellinger, K., Lantos, P. L., Lippa, C. F., Mirra, S. S., et al. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.11.935 · Cited by 724 · cited 1×
“As a pathologic diagnosis, CBD is characterized by widespread deposition of hyperphosphorylated 4-repeat tau in neurons and glia, the latter as astrocytic plaques, in specific topographic areas.(3) Despite various clinical diagnostic criteria (table e-1 on the Neurology® Web site at www.”
BackgroundSelf-citationClinicopathological and imaging correlates of progressive aphasia and apraxia of speech
Josephs, K. A. (2006) · Brain · doi:10.1093/brain/awl078 · Cited by 689
Self-citationThe evolution and pathology of frontotemporal dementia
Kertesz, A., McMonagle, P., Blair, M., Davidson, W., & Munoz, D. G. (2005) · Brain · doi:10.1093/brain/awh598 · Cited by 609
Self-citationClinicopathological correlates in frontotemporal dementia
Hodges, J. R., Davies, R. R., Xuereb, J. H., Casey, B., Broe, M., Bak, T. H., Kril, J. J., & Halliday, G. M. (2004) · Annals of Neurology · doi:10.1002/ana.20203 · Cited by 580 · cited 1×
“The presence of memory impairment in CBD is underscored by numerous series in which the clinical diagnoses of AD or atypical AD proved to be CBD.(12,13,15,16,21,23,39) Acalculia and visuospatial difficulties (with limited details) are rarely described in CBD.”
BackgroundSelf-citationCortical‐basal ganglionic degeneration
Riley, D. E., Lang, A. E., Lewis, A., Resch, L., Ashby, P., Hornykiewicz, O., & Black, S. (1990) · Neurology · doi:10.1212/wnl.40.8.1203 · Cited by 573
Self-citationBoeve, B. F., Lang, A. E., & Litvan, I. (2003) · Annals of Neurology · doi:10.1002/ana.10570 · Cited by 525 · cited 2×
“Alien limb phenomena are included in prior criteria (table e-1), yet what behaviors constitute alien limb phenomena remains a matter of debate.(26) Alien limb phenomena (including complex unintentional limb movements interfering with normal tasks(18) and the sensation that a limb was foreign or had a will of its own(1…”
BackgroundSelf-citation(1994) · Toxicology and Industrial Health · doi:10.1177/074823379401000603 · Cited by 499
GIBB, W. R. G., LUTHERT, P. J., & MARSDEN, C. D. (1989) · Brain · doi:10.1093/brain/112.5.1171 · Cited by 499
Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP
Josephs, K. A., Petersen, R. C., Knopman, D. S., Boeve, B. F., Whitwell, J. L., Duffy, J. R., Parisi, J. E., & Dickson, D. W. (2006) · Neurology · doi:10.1212/01.wnl.0000191307.69661.c3 · Cited by 455
Self-citationClinicopathological correlations in corticobasal degeneration
Lee, S. E., Rabinovici, G. D., Mayo, M. C., Wilson, S. M., Seeley, W. W., DeArmond, S. J., Huang, E. J., Trojanowski, J. Q., Growdon, M. E., Jang, J. Y., et al. (2011) · Annals of Neurology · doi:10.1002/ana.22424 · Cited by 434 · cited 3×
“Visual neglect occurs in CBD,(15,18,20) but also in Alzheimer disease (AD).(20) Language impairments are now recognized as a common and frequently presenting feature of CBD.”
BackgroundSelf-citationPathologic heterogeneity in clinically diagnosed corticobasal degeneration
Boeve, B. F., Maraganore, D. M., Parisi, J. E., Ahlskog, J. E., Graff-Radford, N., Caselli, R. J., Dickson, D. W., Kokmen, E., & Petersen, R. C. (1999) · Neurology · doi:10.1212/wnl.53.4.795 · Cited by 417
Self-citationCorticobasal degeneration: A clinical study of 36 cases
Rinne, J. O., Lee, M. S., Thompson, P. D., & Marsden, C. D. (1994) · Brain · doi:10.1093/brain/117.5.1183 · Cited by 408
Does corticobasal degeneration exist? A clinicopathological re-evaluation
Ling, H., O'Sullivan, S. S., Holton, J. L., Revesz, T., Massey, L. A., Williams, D. R., Paviour, D. C., & Lees, A. J. (2010) · Brain · doi:10.1093/brain/awq123 · Cited by 394 · cited 2×
“The presence of memory impairment in CBD is underscored by numerous series in which the clinical diagnoses of AD or atypical AD proved to be CBD.(12,13,15,16,21,23,39) Acalculia and visuospatial difficulties (with limited details) are rarely described in CBD.”
BackgroundAccuracy of the Clinical Diagnosis of Corticobasal Degeneration: A Clinicopathologic Study
Litvan, I., Agid, Y., Goetz, C., Jankovic, J., Wenning, G. K., Brandel, J. P., Lai, E. C., Verny, M., Ray-Chaudhuri, K., McKee, A., et al. (1997) · Neurology · doi:10.1212/wnl.48.1.119 · Cited by 380
Self-citationWenning, G. K., Litvan, I., Jankovic, J., Granata, R., Mangone, C. A., McKee, A., Poewe, W., Jellinger, K., Chaudhuri, K. R., D'Olhaberriague, L., et al. (1998) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.64.2.184 · Cited by 334 · cited 3×
“Myoclonus in CBD may be superimposed on dystonia(18) and is most commonly described in the upper extremities, but can also be present in the face.(13,18) Descriptions include “focal myoclonus,”(18) “stimulussensitive myoclonus,”(13,16) and “action myoclonus.”
BackgroundResultSelf-citationThe corticobasal degeneration syndrome overlaps progressive aphasia and frontotemporal dementia
Kertesz, A., Martinez-Lage, P., Davidson, W., & Munoz, D. G. (2000) · Neurology · doi:10.1212/wnl.55.9.1368 · Cited by 304
Self-citationImaging correlates of pathology in corticobasal syndrome
Whitwell, J. L., Jack, C. R., Boeve, B. F., Parisi, J. E., Ahlskog, J. E., Drubach, D. A., Senjem, M. L., Knopman, D. S., Petersen, R. C., Dickson, D. W., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181feb2e8 · Cited by 244
Self-citationSnowden, J. S., Thompson, J. C., Stopford, C. L., Richardson, A. M. T., Gerhard, A., Neary, D., & Mann, D. M. A. (2011) · Brain · doi:10.1093/brain/awr189 · Cited by 238
Cognitive and motor assessment in autopsy-proven corticobasal degeneration
Murray, R., Neumann, M., Forman, M. S., Farmer, J., Massimo, L., Rice, A., Miller, B. L., Johnson, J. K., Clark, C. M., Hurtig, H. I., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000259519.78480.c3 · Cited by 218 · cited 10×
“Previous clinical criteria excluded “early dementia” to increase diagnostic specificity,(19) but dementia is now recognized as a presenting and predominant feature in many cases of CBD.(13,15,20)”
BackgroundResultInfluentialSelf-citationDementia as the most common presentation of cortical-basal ganglionic degeneration
Grimes, D. A., Lang, A. E., & Bergeron, C. B. (1999) · Neurology · doi:10.1212/wnl.53.9.1969 · Cited by 218
Self-citationCorticobasal degeneration: Neuropathologic and clinical heterogeneity
Schneider, J. A., Watts, R. L., Gearing, M., Brewer, R. P., & Mirra, S. S. (1997) · Neurology · doi:10.1212/wnl.48.4.959 · Cited by 218 · cited 2×
“Some patients had dysarthria,(18) but for others, few details were provided.(13,15,21) Table 1 Frequency of motor features in available brain banks and studies with ‡5 pathologically confirmed corticobasal degeneration cases”
BackgroundOculomotor function in frontotemporal lobar degeneration, related disorders and Alzheimer's disease
Garbutt, S., Matlin, A., Hellmuth, J., Schenk, A. K., Johnson, J. K., Rosen, H., Dean, D., Kramer, J., Neuhaus, J., Miller, B. L., et al. (2008) · Brain · doi:10.1093/brain/awn047 · Cited by 211
Self-citationClinical Presentation and Pharmacological Therapy in Corticobasal Degeneration
Kompoliti, K., Goetz, C. G., Boeve, B. F., Maraganore, D. M., Ahlskog, J. E., Marsden, C. D., Bhatia, K. P., Greene, P. E., Przedborski, S., Seal, E. C., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.7.957 · Cited by 196 · cited 1×
“Tremor phenotype in CBD is poorly characterized, but a CBS series suggests that it differs from the typical rest tremor of Parkinson disease (PD).(25) Lowamplitude action myoclonus may resemble tremor.”
BackgroundSelf-citationNovel splicing mutation in the progranulin gene causing familial corticobasal syndrome
Masellis, M., Momeni, P., Meschino, W., Heffner, R., Elder, J., Sato, C., Liang, Y., George-Hyslop, P. S., Hardy, J., Bilbao, J., et al. (2006) · Brain · doi:10.1093/brain/awl276 · Cited by 195
Accuracy of clinical diagnosis of progressive supranuclear palsy
Osaki, Y., Ben‐Shlomo, Y., Lees, A. J., Daniel, S. E., Colosimo, C., Wenning, G., & Quinn, N. (2004) · Movement Disorders · doi:10.1002/mds.10680 · Cited by 183 · cited 1×
“While PSPS is a CBD phenotype, it is much more likely to represent PSP than CBD.(58) Thus, PSPS is an acceptable phenotype only in the p-CBD criteria.”
BackgroundNeuropsychiatric features of corticobasal degeneration
Litvan, I., Cummings, J. L., & Mega, M. (1998) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.65.5.717 · Cited by 179
Self-citationDynamic properties of horizontal and vertical eye movements in parkinsonian syndromes
Rottach, K. G., Riley, D. E., DiScenna, A. O., Zivotofsky, A. Z., & Leigh, R. J. (1996) · Annals of Neurology · doi:10.1002/ana.410390314 · Cited by 178
Self-citationRebeiz, J. J., Kolodny, E. H., & Ep, R. (1967) · PubMed · Cited by 169
Komori, T., Arai, N., Oda, M., Nakayama, H., Mori, H., Yagishita, S., Takahashi, T., Amano, N., Murayama, S., Murakami, S., et al. (1998) · Acta Neuropathologica · doi:10.1007/s004010050911 · Cited by 165
Signature Tau Neuropathology in Gray and White Matter of Corticobasal Degeneration
Forman, M. S., Zhukareva, V. A., Bergeron, C., Chin, S. S., Grossman, M., Clark, C. M., Lee, V. M. ‐., & Trojanowski, J. Q. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)61154-6 · Cited by 159 · cited 2×
“The presence of memory impairment in CBD is underscored by numerous series in which the clinical diagnoses of AD or atypical AD proved to be CBD.(12,13,15,16,21,23,39) Acalculia and visuospatial difficulties (with limited details) are rarely described in CBD.”
BackgroundSelf-citationLongitudinal ocular motor study in corticobasal degeneration and progressive supranuclear palsy
Rivaud-Péchoux, S., Vidailhet, M., Gallouedec, G., Litvan, I., Gaymard, B., & Pierrot-Deseilligny, C. (2000) · Neurology · doi:10.1212/wnl.54.5.1029 · Cited by 159
Self-citationThe myoclonus in corticobasal degeneration: Evidence for two forms of cortical reflex myoclonus
Thompson, P. D., Day, B. L., Rothwell, J. C., Brown, P., Britton, T. C., & Marsden, C. D. (1994) · Brain · doi:10.1093/brain/117.5.1197 · Cited by 157
Rapidly Progressive Neurodegenerative Dementias
Josephs, K. A., Ahlskog, J. E., Parisi, J. E., Boeve, B. F., Crum, B. A., Giannini, C., & Petersen, R. C. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.534 · Cited by 155 · cited 1×
“In a series of patients with rapidly progressive dementia, neither of the patients with CBD died in the first year, in contrast to the 8 patients with Creutzfeldt-Jakob disease (CJD) (of 22 cases) who died within 12 months of onset.(52) Table 3 Frequency of other features in available brain banks and studies with ‡5 p…”
ResultSelf-citationSpeech errors in progressive non-fluent aphasia
Ash, S., McMillan, C., Gunawardena, D., Avants, B., Morgan, B., Khan, A., Moore, P., Gee, J., & Grossman, M. (2010) · Brain and Language · doi:10.1016/j.bandl.2009.12.001 · Cited by 130
Self-citationLanguage function and dysfunction in corticobasal degeneration
Graham, N. L., Bak, T., Patterson, K., & Hodges, J. R. (2003) · Neurology · doi:10.1212/01.wnl.0000081230.09863.ed · Cited by 124
Self-citationSaccade Abnormalities in Autopsy-Confirmed Frontotemporal Lobar Degeneration and Alzheimer Disease
Garbutt, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.1021 · Cited by 114 · cited 1×
“Antisaccade performance was abnormal in all cases.(46) Upper motor neuron signs are another feature described in CBD cases (table 3), but since they also occur in other atypical parkinsonisms, they are unlikely to be a helpful distinguishing sign.”
BackgroundThe Diagnosis and Course of Frontotemporal Dementia
Kertesz, A., Blair, M., McMonagle, P., & Munoz, D. G. (2007) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31806547eb · Cited by 110 · cited 1×
“Aphasic patients with CBD may progress to mutism.(13,15,36) Apraxia of speech (AOS) has also been described in CBD on its own and coexisting with aphasia,(20,32) though challenges in diagnosing AOS limit efforts to estimate its frequency.”
BackgroundSelf-citationCorticobasal degeneration and progressive aphasia
McMonagle, P., Blair, M., & Kertesz, A. (2006) · Neurology · doi:10.1212/01.wnl.0000240215.43492.01 · Cited by 98
Self-citationDystonia in corticobasal degeneration
Vanek, Z., & Jankovic, J. (2001) · Movement Disorders · doi:10.1002/mds.1038 · Cited by 90
Corticobasal Syndrome Associated With the A9D Progranulin Mutation
Spina, S., Murrell, J. R., Huey, E. D., Wassermann, E. M., Pietrini, P., Grafman, J., & Ghetti, B. (2007) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/nen.0b013e3181567873 · Cited by 87
STIMULUS-SENSITIVE MYOCLONUS IN AKINETIC-RIGID SYNDROMES
Chen, R. E., Ashby, P., & Lang, A. E. (1992) · Brain · doi:10.1093/brain/115.6.1875 · Cited by 79
Self-citationRiley, D. E., & Lang, A. E. (2000) · PubMed · Cited by 78
Self-citationMutations in Progranulin Gene: Clinical, Pathological, and Ribonucleic Acid Expression Findings
de Munaín, A. L., Alzualde, A., Gorostidi, A., Otaegui, D., Ruiz‐Martínez, J., Indakoetxea, B., Ferrer, I., Pérez‐Tur, J., Sáenz, A., Bergareche, A., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.08.015 · Cited by 74
Parkinson's disease & movement disorders
Jankovic, J. J., & TOLOSA, E. S. (2015) · Wolters Kluwer eBooks · Cited by 73
Self-citationCalculation impairment in neurodegenerative diseases
Halpern, C. H., McMillan, C. T., Moore, P., Dennis, K., & Grossman, M. (2003) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00416-1 · Cited by 60 · cited 1×
“Sustained levodopa responsiveness—related to parkinsonism—is an exclusion criterion in prior diagnostic schemes.(4,5,9,10,26) Patients with CBD may demonstrate transient mild to moderate improvement with levodopa therapy and rarely develop levodopainduced dyskinesias,(16) but a sustained response is rare.”
BackgroundSelf-citationCortical‐basal ganglionic degeneration
Okuda, B., & Tachibana, H. (1995) · Neurology · doi:10.1212/wnl.45.5.1033-b · Cited by 58
Corticobasal degeneration: clinical aspects
Bak, T. H., & Hodges, J. R. (2008) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)01247-x · Cited by 56 · cited 1×
“Sustained levodopa responsiveness—related to parkinsonism—is an exclusion criterion in prior diagnostic schemes.(4,5,9,10,26) Patients with CBD may demonstrate transient mild to moderate improvement with levodopa therapy and rarely develop levodopainduced dyskinesias,(16) but a sustained response is rare.”
BackgroundSelf-citationRoss, A. H., Elston, J. S., Marion, M.-H., & Malhotra, R. (2010) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2010.03.008 · Cited by 46 · cited 1×
“Patients with CBD may also have orobuccal apraxia or “apraxia of eyelid opening,”(13,15,16,18,21,24) though the latter is often a misnomer representing pretarsal blepharospasm rather than true apraxia.(31) Alien limb phenomena are included in prior criteria (table e-1), yet what behaviors constitute alien limb phenome…”
BackgroundLladó, A., Sánchez‐Valle, R., Rey, M. J., Ezquerra, M., TOLOSA, E. S., Ferrer, I., Molinuevo, J. L., & for the Catalan collaborative Study Group for FTLD* (2008) · Journal of Neurology · doi:10.1007/s00415-008-0565-8 · Cited by 43
Self-citationArmstrong, R. A. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7392 · Cited by 36
Tsuchiya, K., Murayama, S., Mitani, K., Oda, T., Arima, K., Mimura, M., Nagura, H., Haga, C., Akiyama, H., Yamanouchi, H., et al. (2005) · Acta Neuropathologica · doi:10.1007/s00401-004-0966-4 · Cited by 34 · cited 1×
“Ideomotor apraxia is the most commonly described apraxia in CBD(15,16,18) with one series also describing limbkinetic apraxia.(24) The presence of limb dystonia, bradykinesia, and rigidity can make assessing ideomotor apraxia challenging and diagnosing limbkinetic apraxia impossible.”
BackgroundVanVoorst, W. A., Greenaway, M. C., Boeve, B. F., Ivnik, R. J., Parisi, J. E., Ahlskog, J. E., Knopman, D. S., Dickson, D. W., Petersen, R. C., Smith, G. E., et al. (2007) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2007.09.006 · Cited by 34 · cited 1×
“Neuropsychological testing in one study revealed that patients with CBD had difficulties with learning tasks, word fluency, verbal comprehension, perceptual organization, and cognitive flexibility.(38) Another study showed impairments in executive, language, and visuospatial domains with relatively preserved episodic…”
BackgroundSelf-citationEye movement disorders in corticobasal degeneration.
Vidailhet, M., & Rivaud-Péchoux, S. (2000) · PubMed · Cited by 21
Self-citationBoeve, B. F. (2005) · Humana Press eBooks · doi:10.1385/1-59259-834-x:309 · Cited by 15
(2000) · doi:10.1002/1531-8249(200012)48:6
Research works printed but not linked: 2
- Watts RL, Mirra SS, Richardson EP. Cortical-basal gan- glionic degeneration. In: Marsden CD, Fahn S, eds. Move- ment Disorders, vol 3. Oxford: Butterworth Heinemann; 1994:282-299.
- Hodges JR. Clinico-pathological correlations in frontotempo- ral dementia: an update on the Cambridge series and review of the literature. Acta Neuropsychol 2011;9:177-191.
Cited by
Pathology of Neurodegenerative Diseases
Dugger, B. N., & Dickson, D. W. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028035 · Cited by 1,665
“, atypical AD), the antemortem diagnostic accuracy of CBD is poor, and recent clinical criteria reflect this fact (Armstrong et al. 2013).”
BackgroundSelf-citationBhatia, K. P., Bain, P., Bajaj, N., Elble, R. J., Hallett, M., Louis, E. D., Raethjen, J., Stamelou, M., Testa, C. M., Deuschl, G., et al. (2018) · Movement Disorders · doi:10.1002/mds.27121 · Cited by 1,575
Self-citationJanelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., Chai, X., Proctor, N. K., Eichenlaub, U., Zetterberg, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0755-1 · Cited by 1,247
“2017) and corticobasal syndrome (CBS) (fulfilling the criteria defined by Armstrong et al.(Armstrong et al. 2013)).”
BackgroundClinical Neurology and Epidemiology of the Major Neurodegenerative Diseases
Erkkinen, M. G., Kim, M.-O., & Geschwind, M. D. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a033118 · Cited by 1,124
“…supranuclear palsy syndrome Three of (i) axial or symmetric limb rigidity or akinesia, (ii) postural instability or falls, (iii) urinary incontinence, (iv) behavioral changes, (v) supranuclear gaze palsy or decreased velocity of vertical saccades Source: Litvan et al. 1996a; Armstrong et al. 2013.”
BackgroundClinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group
Dubois, B., Villain, N., Frisoni, G. B., Rabinovici, G. D., Sabbagh, M., Cappa, S., Bejanin, A., Bombois, S., Epelbaum, S., Teichmann, M., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00066-1 · Cited by 1,051
“Other phenotypes, including the behavioural/dysexecutive variant 70,71 , the cortico-basal variant 72,73 , and the other variants of primary progressive aphasia 69,74 (Supplementary Figure 1), are less commonly related to AD pathology (uncommon AD phenotypes).”
Background
Metadata
- Authors
- Armstrong, M. J., Litvan, I., Lang, A. E., Bak, T. H., Bhatia, K. P., Borroni, B., Boxer, A. L., Dickson, D. W., Grossman, M., Hallett, M., Josephs, K. A., Kertesz, A., Lee, S. E., Miller, B. L., Reich, S. G., Riley, D. E., Tolosa, E., Tröster, A. I., Vidailhet, M., & Weiner, W. J.
- Affiliations
- Toronto Western Hospital (CA)
- National Institutes of Health (US)
- ORCID
- Venue
- Neurology
- Published
- 2013-01-29
- Volume
- 80
- Issue
- 5
- Pages
- 496-503
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- PMC
- PMC3590050
- OpenAlex
- W2144707045
- Cited by
- 1,904
- References
- 58
- Citations by year
- 2026: 160 · 2025: 193 · 2024: 184 · 2023: 166 · 2022: 177 · 2021: 190 · 2020: 170 · 2019: 167 · 2018: 117 · 2017: 125 · 2016: 82 · 2015: 79 · 2014: 62 · 2013: 26
- FWCI
- 59.01
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Neurology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Funders
- National Institute on Aging (K23AG039414, R01AG031278, R01AG038791, P01AG032953, P01AG019724)
- National Institute of Neurological Disorders and Stroke (P50NS072187, R01NS044266)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- corticobasal degeneration, corticobasal syndrome, clinical criteria, tauopathy, clinicopathological correlation, dementia with Lewy bodies, frontotemporal lobar degeneration
- MeSH terms
- Aged, Basal Ganglia, Cerebral Cortex, Cognition Disorders, Family Health, Female, Humans, Language Disorders, Male, Middle Aged, Neurologic Examination, Phenotype, Retrospective Studies, Databases, Factual, Age of Onset, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.